| Ryan Robert Walsh, MD, PHD | |
|
240 W Thomas Rd # 404, Phoenix, AZ 85013 | |
| (602) 406-6262 | |
| (602) 406-6261 |
| Full Name | Ryan Robert Walsh |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 240 W Thomas Rd # 404, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013129972 | NPI | - | NPPES |
| Entity Name | Sjhmc Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326098005 PECOS PAC ID: 4486646197 Enrollment ID: O20040401001189 |
News Archive
Hysterectomy elevates the risk of stroke and coronary heart disease in young women when combined with the removal of both ovaries in the same operation. This fact provides the background for the epidemiological report by Andreas Stang and colleagues on hysterectomy rates in Germany, which appears in the current issue of Deutsches Ärzteblatt International.
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
The Shareholders of Imagin Molecular Corporation ("IMGM") have approved, through a consent of over 51% of shareholder vote, certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a 1 for 100 basis into Positron common shares.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
An interdisciplinary, international group of researchers has found new biophysical markers that could help improve the understanding of treatments for sickle cell disease, a step toward developing better methods for treating the inherited blood disorder that affects an estimated 80,000 to 100,000 Americans each year.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Robert Walsh, MD, PHD 240 W Thomas Rd # 404, Phoenix, AZ 85013-4407 Ph: (602) 406-6262 | Ryan Robert Walsh, MD, PHD 240 W Thomas Rd # 404, Phoenix, AZ 85013 Ph: (602) 406-6262 |
News Archive
Hysterectomy elevates the risk of stroke and coronary heart disease in young women when combined with the removal of both ovaries in the same operation. This fact provides the background for the epidemiological report by Andreas Stang and colleagues on hysterectomy rates in Germany, which appears in the current issue of Deutsches Ärzteblatt International.
Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.
The Shareholders of Imagin Molecular Corporation ("IMGM") have approved, through a consent of over 51% of shareholder vote, certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a 1 for 100 basis into Positron common shares.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
An interdisciplinary, international group of researchers has found new biophysical markers that could help improve the understanding of treatments for sickle cell disease, a step toward developing better methods for treating the inherited blood disorder that affects an estimated 80,000 to 100,000 Americans each year.
› Verified 9 days ago
Dr. George David Goldberg, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2145 E Kaler Dr, Phoenix, AZ 85020 Phone: 602-943-2400 | |
Andrea Oliver Skelton, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 16620 N 40th St Ste H4, Phoenix, AZ 85032 Phone: 602-464-9576 Fax: 602-626-8901 | |
Mr. Joseph Andrew Vitagliano, PA-C Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1110 E Missouri Ave Ste 110, Phoenix, AZ 85014 Phone: 480-542-8202 | |
Robin Laurie Mcfarlane, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 602-839-2266 | |
Kevin Yang, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2601 E Roosevelt St, Phoenix, AZ 85008 Phone: 602-344-5011 | |
Dr. Michael A Stein, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 240 W Thomas Rd # 404, Phoenix, AZ 85013 Phone: 602-406-6262 | |
Dr. Lee Ann Kelley, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 4602 N 16th St Ste 100, Phoenix, AZ 85016 Phone: 602-795-1834 Fax: 602-795-2608 |